Home β€Ί Healthcare β€Ί Healthcare IT β€Ί Cancer Registry Software Market

Cancer Registry Software Market Size, Share, Opportunities, And Trends By Type (Integrated Software, Standalone Software), By Deployment mode (On-premise, Cloud-based), By Database (Commercial database, Public database), By Functionality (Cancer Reporting, Patient Care Management, Product Outcome Evaluation, Medical Research and Clinical Studies), By End User (Government Organizations & Third-party Administrators, Hospitals & Medical Practices, Pharmaceutical, Biotechnology, & Medical Device Companies, Private Payers, Research Centers), And By Geography - Forecasts From 2024 To 2029

πŸ“₯ Download Free SampleπŸ’¬ Speak to Analyst
$4,250
Single User License
Access Full Insights
Report OverviewSegmentationTable of ContentsCustomize Report

Report Overview

The cancer registry software market is witnessing significant growth driven by the increasing burden of cancer worldwide and the need for robust data management solutions. Cancer registry software plays a pivotal role in collecting, storing, and analyzing data related to cancer cases, treatments, and outcomes. These software solutions provide healthcare institutions, research organizations, and government agencies with valuable insights into cancer trends, patient demographics, and the effectiveness of treatment protocols.

With advancements in technology, including the integration of artificial intelligence and machine learning capabilities, cancer registry software offers enhanced functionality and accuracy in data analysis. Moreover, the growing emphasis on population health management and evidence-based decision-making further propels the demand for cancer registry software. As cancer continues to pose a significant global health challenge, the cancer registry software market is expected to continue its upward trajectory in the coming years, supporting efforts to improve cancer prevention, diagnosis, and treatment outcomes.

Market Drivers

  • Rising rate of cancer cases

According to projections from the International Agency for Research on Cancer (IARC) as of July 2021, it is anticipated that by 2040, the worldwide incidence of cancer will rise to 27.5 million new cases, with 16.3 million deaths attributed to the disease. This substantial increase in cancer prevalence underscores the growing need for cancer registry software, which offers valuable insights into cancer trends and treatment approaches.

  • Operational disruptions
  • In January 2022, a research study titled "Impact of the COVID-19 Pandemic on Population-based Cancer Registry" revealed that numerous cancer registries experienced operational disruptions in the initial stages of the pandemic. To safeguard the sustainability of cancer surveillance globally, governments must demonstrate ongoing support for registry operations as a crucial tool in disease management. Transitioning towards electronic reporting systems is also advocated to enhance efficiency and resilience in cancer surveillance efforts.

North America is anticipated to hold a significant share of the market

The North American region is projected to lead the market, driven by the rising prevalence of chronic conditions such as cancer and the introduction of new products. As per the Cancer Statistics 2021 report by the American Cancer Society Journal, approximately 1.9 million new cancer cases and 608,570 cancer-related deaths were recorded in the United States, significantly influencing market growth. Additionally, data from Globocan 2020 indicates that the country had 274,364 new cancer cases in 2020, with projections suggesting an increase to 400,564 by 2040. Therefore, the escalating burden of cancer cases in the country is anticipated to propel market expansion.

Market Developments

  • In May 2022, Kaiku Health and Roche announced a collaborative partnership focused on digital patient monitoring and management (DPMM). The objective of this partnership is to leverage digital tools to enhance real-time symptom management for both patients and healthcare providers (HCPs), enhance patient support services, and deliver personalized cancer care to cancer clinics and patients worldwide.
  • In March 2022, Elekta announced that the National Health Service Supply Chain (NHSSC) had procured several licenses for Elekta's ProKnow software solution. This software centralizes and analyzes radiotherapy data within a secure and scalable platform, making it accessible to radiation oncology facilities across NHS England (NHSE).
  • In August 2021, the International Agency for Research on Cancer (IARC) collaborated with The Northern Ireland Cancer Registry to develop new software aimed at enhancing cancer staging. The goal is to bolster national cancer control efforts through the improved collection of standardized and comparable data.

Market Segmentation

  • By Type
    • Integrated Software
    • Standalone Software
  • By Deployment mode
    • On-premise
    • Cloud-based
  • By Database
    • Commercial database
    • Public database
  • By Functionality
    • Cancer Reporting
    • Patient Care Management
    • Product Outcome Evaluation
    • Medical Research and Clinical Studies
  • By End User
    • Government Organizations & Third-party Administrators
    • Hospitals & Medical Practices
    • Pharmaceutical, Biotechnology, & Medical Device Companies
    • Private Payers
    • Research Centers
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • France
      • Italy
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Taiwan
      • Thailand
      • Indonesia
      • Others

REPORT DETAILS

Report ID:KSI061616697
Published:Feb 2024
Pages:147
Format:PDF, Excel, PPT, Dashboard
πŸ“₯ Download SampleπŸ“ž Speak to AnalystπŸ“§ Request Customization

Need Assistance?

Our research team is available to answer your questions.

Contact Us

Frequently Asked Questions

The Cancer Registry Software Size, Share, Opportunities, And Trends By Type (Integrated Software, Standalone Software), By Deployment mode (On-premise, Cloud-based), By Database (Commercial database, Public database), By Functionality (Cancer Reporting, Patient Care Management, Product Outcome Evaluation, Medical Research and Clinical Studies), By End User (Government Organizations & Third-party Administrators, Hospitals & Medical Practices, Pharmaceutical, Biotechnology, & Medical Device Companies, Private Payers, Research Centers), And By Geography - Forecasts From 2024 To 2029 Market is expected to reach significant growth by 2030.

Key drivers include increasing demand across industries, technological advancements, favorable government policies, and growing awareness among end-users.

This report covers North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa with detailed country-level analysis.

This report provides analysis and forecasts from 2025 to 2030.

The report profiles leading companies operating in the market including major industry players and emerging competitors.

Related Reports

Healthcare

United Kingdom Electronic Health Records (EHR) Market - Strategic Insights and Forecasts (2025-2030)

Aug 2025
Healthcare

Spain Electronic Health Records (EHR) Market - Strategic Insights and Forecasts (2025-2030)

Aug 2025
Healthcare

Italy Electronic Health Records (EHR) Market - Strategic Insights and Forecasts (2025-2030)

Aug 2025
Healthcare

Germany Electronic Health Records (EHR) Market - Strategic Insights and Forecasts (2025-2030)

Aug 2025
View All Reports